Modulators of adp-dependent glucokinase (adpgk) and glycerol-3-phosphate dehydrogenase (gpd2) for therapy
AssigneeDeutsches Krebsforschungszentrum Stiftung Des öFfentlichen Recht
InventorsPeter Krammer, Marcin M. Kaminski, Karsten Gulow, Sven W. Sauer
Life of this patent
Estimating the term…
Abstract
Described are compounds capable of modulating (a) the biological activity of ADP-dependent glucokinase (ADPGK) and/or glycerol-3-phosphate dehydrogenase (GPD2) or (b) the expression of the gene encoding ADPGK or GPD2 for use in treating a disease (a) associated with aberrant cell proliferation, e.g., a neoplasm, or (b) of the immune system, e.g., an autoimmune disease.
Claims4
A method of treatment comprising administering a compound capable of modulating (a) the biological activity of ADP-dependent glucokinase (ADPGK) or (b) the expression of the gene encoding ADPGK to a patient in need thereof,
- wherein the patient has a neoplasm, an autoimmune disease or Graft versus-Host-Disease (GvHD), and
- wherein said compound is
- an antisense oligonucleotide,
- siRNA reducing or inhibiting the expression of the gene encoding ADPGK,
- an antibody directed against ADPGK or a fragment thereof having the same specificity,
- an inactive version of ADPGK, or
- a polynucleic acid encoding an inactive version of ADPGK.
Dependencies are inferred from the claim text.